Eon Labs Begins Shipping Itraconazole Capsules

    Business Editors/Health Editors

    LAKE SUCCESS, N.Y.--(BUSINESS WIRE)--Feb. 9, 2005--Eon Labs, Inc. (Nasdaq: ELAB) announced today that it began shipping Itraconazole 100mg capsules, the generic equivalent to Sporanox(R)* capsules. As the first company to file an ANDA with a Paragraph IV patent certification for this product, Eon Labs is entitled to 180 days of market exclusivity.
    In July 2004 the U.S. District Court for the Eastern District of New York granted judgment in favor of Eon Labs ruling that, while the validity of the patent was upheld, the Company's Itraconazole 100mg capsules do not infringe Janssen Pharmaceutica N.V. and Janssen Pharmaceutica Products, L.P.'s U.S. Patent No. 5,633,015. Janssen is challenging the District Court decision in the United States Court of Appeals for the Federal Circuit.
    Eon Labs is a generic pharmaceutical company specializing in developing, licensing, manufacturing, selling and distributing a broad range of prescription pharmaceutical products. For press releases and other company information, visit the Eon Labs, Inc. website at www.eonlabs.com.

    Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995: This release contains statements that are forward-looking in nature which express the beliefs and expectations of management. Such statements are based on current plans, estimates and expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. These factors and additional information are discussed in the Company's filings with the Securities and Exchange Commission and statements in this release should be evaluated in light of these important factors. Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

    * Sporanox(R) is a registered trademark of Johnson & Johnson, which is not affiliated with Eon Labs, Inc.

--30--RC/ny*

CONTACT: Eon Labs, Inc. Christopher LoSardo, 516-478-9712 www.eonlabs.com

KEYWORD: NEW YORK INDUSTRY KEYWORD: PHARMACEUTICAL MEDICAL PRODUCT SOURCE: Eon Labs, Inc.

Copyright Business Wire 2005